Rilzabrutinib delivers beneficial effects in immune thrombocytopenia
09 Jan 2025
bởiStephen Padilla
A phase III trial (LUNA 3) has demonstrated robust therapeutic effects for rilzabrutinib in patients with previously untreated immune thrombocytopenia (ITP). Use of this BTK inhibitor results in rapid and durable platelet response, reduced bleeding and need for rescue therapy, improved physical fatigue and quality of life (QoL), and favourable safety and tolerability.
